|
1
|
Horikawa YT, Panneerselvam M, Kawaraguchi
Y, Tsutsumi YM, Ali SS, Balijepalli RC, Murray F, Head BP, Niesman
IR, Rieg T, et al: Cardiac-specific overexpression of caveolin-3
attenuates cardiac hypertrophy and increases natriuretic peptide
expression and signaling. J Am Coll Cardiol. 57:2273–2283. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song KS, Scherer PE, Tang Z, Okamoto T, Li
S, Chafel M, Chu C, Kohtz DS and Lisanti M: Expression of
caveolin-3 in skeletal, cardiac, and smooth muscle cells.
Caveolin-3 is a component of the sarcolemma and co-fractionates
with dystrophin and dystrophin-associated glycoproteins. J Biol
Chem. 271:15160–15165. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Talukder MA, Preda M, Ryzhova L, Prudovsky
I and Pinz IM: Heterozygous caveolin-3 mice show increased
susceptibility to palmitate-induced insulin resistance.
Physiological reports. 4:e127362016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oshikawa J, Otsu K, Toya Y, Tsunematsu T,
Hankins R, Kawabe J, Minamisawa S, Umemura S, Hagiwara Y and
Ishikawa Y: Insulin resistance in skeletal muscles of
caveolin-3-null mice. Proc Natl Acad Sci USA. 101:12670–12675.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patel HH, Murray F and Insel PA:
G-protein-coupled receptor-signaling components in membrane raft
and caveolae microdomains. Handb Exp Pharmacol. 167–184. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lei S, Li H, Xu J, Liu Y, Gao X, Wang J,
Ng KF, Lau WB, Ma XL, Rodrigues B, et al: Hyperglycemia-induced
protein kinase C β2 activation induces diastolic cardiac
dysfunction in diabetic rats by impairing caveolin-3 expression and
Akt/eNOS signaling. Diabetes. 62:2318–2328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gervásio OL, Whitehead NP, Yeung EW,
Phillips WD and Allen DG: TRPC1 binds to caveolin-3 and is
regulated by Src kinase-role in Duchenne muscular dystrophy. J Cell
Sci. 121:2246–2255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su W, Zhang Y, Zhang Q, Xu J, Zhan L, Zhu
Q, Lian Q, Liu H, Xia ZY, Xia Z and Lei S: N-acetylcysteine
attenuates myocardial dysfunction and postischemic injury by
restoring caveolin-3/eNOS signaling in diabetic rats. Cardiovasc
Diabetol. 15:1462016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Woodman SE, Sotgia F, Galbiati F, Minetti
C and Lisanti MP: Caveolinopathies: Mutations in caveolin-3 cause
four distinct autosomal dominant muscle diseases. Neurology.
62:538–543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Milone M, McEvoy KM, Sorenson EJ and Daube
JR: Myotonia associated with caveolin-3 mutation. Muscle Nerve.
45:897–900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woodman SE, Park DS, Cohen AW, Cheung MW,
Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, et
al: Caveolin-3 knock-out mice develop a progressive cardiomyopathy
and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem.
277:38988–38997. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Capozza F, Combs TP, Cohen AW, Cho YR,
Park SY, Schubert W, Williams TM, Brasaemle DL, Jelicks LA, Scherer
PE, et al: Caveolin-3 knockout mice show increased adiposity and
whole body insulin resistance, with ligand-induced insulin receptor
instability in skeletal muscle. Am J Physiol Cell Physiol.
288:C1317–C1331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nader NS and Kumar S: Type 2 diabetes
mellitus in children and adolescents: Where do we stand with drug
treatment and behavioral management? Curr Diab Rep. 8:383–388.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang Q, Huang YY, Deng YF, Xian J, Lu WS
and Wei HQ: Caveolin-3 gene polymorphism in Chinese H an diabetic
patients. J Pract Med. 30:1757–1759. 2014.
|
|
15
|
Shang L, Chen T, Deng Y, Huang Y, Huang Y,
Xian J, Lu W, Yang L and Huang Q: Caveolin-3 promotes
glycometabolism, growth and proliferation in muscle cells. PLoS
One. 12:e01890042017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng YF, Huang YY, Lu WS, Huang YH, Xian
J, Wei HQ and Huang Q: The Caveolin-3 P104L mutation of LGMD-1C
leads to disordered glucose metabolism in muscle cells. Biochem
Biophys Res Commun. 486:218–223. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koistinen HA, Galuska D, Chibalin AV, Yang
J, Zierath JR, Holman GD and Wallberg-Henriksson H:
5-amino-imidazole carboxamide riboside increases glucose transport
and cell-surface GLUT4 content in skeletal muscle from subjects
with type 2 diabetes. Diabetes. 52:1066–1072. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim HS, Kim HJ, Kim YS, Park SC, Harris R
and Kim CK: Caveolin, GLUT4 and insulin receptor protein content in
human arm and leg muscles. Eur J Appl Physiol. 106:173–179. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Visvanathan R, Jayathilake C and Liyanage
R: A simple microplate-based method for the determination of
alpha-amylase activity using the glucose assay kit (GOD method).
Food Chem. 211:853–859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo J, Xu Q, Jiang B, Zhang R, Jia X, Li
X, Wang L, Guo C, Wu N and Shi D: Selectivity, cell permeability
and oral availability studies of novel bromophenol derivative HPN
as protein tyrosine phosphatase 1B inhibitor. Br J Pharmacol.
175:140–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng W, Mao G, Li Q, Wang W, Chen Y, Zhao
T, Li F, Zou Y, Wu H, Yang L and Wu X: Effects of chromium malate
on glycometabolism, glycometabolism-related enzyme levels and lipid
metabolism in type 2 diabetic rats: A dose-response and curative
effects study. J Diabetes Investig. 6:396–407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ben Jemaa A, Bouraoui Y, Sallami S, Banasr
A, Nouira Y, Horchani A and Oueslati R: PSMA-PSA clones controlled
by full Akt phosphorylation (T308+,S473+) recapitulate molecular
features of human prostate cancer. Tunis Med. 93:556–564.
2015.PubMed/NCBI
|
|
23
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guertin DA, Stevens DM, Thoreen CC, Burds
AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ and Sabatini DM:
Ablation in mice of the mTORC components raptor, rictor, or mLST8
reveals that mTORC2 is required for signaling to Akt-FOXO and
PKCalpha, but not S6K1. Dev Cell. 11:859–871. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chu N, Salguero AL, Liu AZ, Chen Z,
Dempsey DR, Ficarro SB, Alexander WM, Marto JA, Li Y, Amzel LM, et
al: Akt kinase activation mechanisms revealed using protein
semisynthesis. Cell. 174:897–907.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spisni E, Tomasi V, Cestaro A and Tosatto
SC: Structural insights into the function of human caveolin 1.
Biochem Biophys Res Commun. 338:1383–1390. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim JH, Schlebach JP, Lu Z, Peng D,
Reasoner KC and Sanders CR: A pH-mediated topological switch within
the N-terminal domain of human caveolin-3. Biophys J.
110:2475–2485. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vaidyanathan R, Van Ert H, Haq KT, Morotti
S, Esch S, McCune EC, Grandi E and Eckhardt LL: Inward rectifier
potassium channels (Kir2.x) and caveolin-3 domain-specific
interaction: Implications for purkinje cell-dependent ventricular
arrhythmias. Circ Arrhythm Electrophysiol. 11:e0058002018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fischer D, Schroers A, Blümcke I, Urbach
H, Zerres K, Mortier W, Vorgerd M and Schröder R: Consequences of a
novel caveolin-3 mutation in a large German family. Ann Neurol.
53:233–241. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Couet J, Li S, Okamoto T, Ikezu T and
Lisanti MP: Identification of peptide and protein ligands for the
caveolin-scaffolding domain. Implications for the interaction of
caveolin with caveolae-associated proteins. J Biol Chem.
272:6525–6533. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Couet J, Sargiacomo M and Lisanti MP:
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins.
Caveolin binding negatively regulates tyrosine and serine/threonine
kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Minetti C, Sotgia F, Bruno C, Scartezzini
P, Broda P, Bado M, Masetti E, Mazzocco M, Egeo A, Donati MA, et
al: Mutations in the caveolin-3 gene cause autosomal dominant
limb-girdle muscular dystrophy. Nat Genet. 18:365–368. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hernández-Deviez DJ, Martin S, Laval SH,
Lo HP, Cooper ST, North KN, Bushby K and Parton RG: Aberrant
dysferlin trafficking in cells lacking caveolin or expressing
dystrophy mutants of caveolin-3. Hum Mol Genet. 15:129–142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oh YS, Cho KA, Ryu SJ, Khil LY, Jun HS,
Yoon JW and Park SC: Regulation of insulin response in skeletal
muscle cell by caveolin status. J Cell Biochem. 99:747–758. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X and Wang Y: Glycosylation quality
control by the Golgi structure. J Mol Biol. 428:3183–3193. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao Y, Zhang M, Wu T, Xu M, Cai H and
Zhang Z: Effects of D-pinitol on insulin resistance through the
PI3K/Akt signaling pathway in type 2 diabetes mellitus rats. J
Agric Food Chem. 63:6019–6026. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang M, Ren Y, Lin Z, Tang C, Jia Y, Lai
Y, Zhou T, Wu S, Liu H, Yang G and Li L: Krüppel-like factor 14
increases insulin sensitivity through activation of PI3K/Akt signal
pathway. Cell Signal. 27:2201–2208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tan Z, Zhou LJ, Mu PW, Liu SP, Chen SJ, Fu
XD and Wang TH: Caveolin-3 is involved in the protection of
resveratrol against high-fat-diet-induced insulin resistance by
promoting GLUT4 translocation to the plasma membrane in skeletal
muscle of ovariectomized rats. J Nutr Biochem. 23:1716–1724. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ferrannini E, Bjorkman O, Reichard GA Jr,
Pilo A, Olsson M, Wahren J and DeFronzo RA: The disposal of an oral
glucose load in healthy subjects. A quantitative study. Diabetes.
34:580–588. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gazzerro E, Sotgia F, Bruno C, Lisanti MP
and Minetti C: Caveolinopathies: From the biology of caveolin-3 to
human diseases. Eur J Hum Genet. 18:137–145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee J and Kim MS: The role of GSK3 in
glucose homeostasis and the development of insulin resistance.
Diabetes Res Clin Pract. 77 (Suppl 1):S49–S57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Biddinger SB and Kahn CR: From mice to
men: Insights into the insulin resistance syndromes. Annu Rev
Physiol. 68:123–158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Boura-Halfon S and Zick Y: Phosphorylation
of IRS proteins, insulin action, and insulin resistance. Am J
Physiol Endocrinol Metab. 296:E581–E591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saltiel AR and Kahn CR: Insulin signalling
and the regulation of glucose and lipid metabolism. Nature.
414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gual P, Le Marchand-Brustel Y and Tanti
JF: Positive and negative regulation of insulin signaling through
IRS-1 phosphorylation. Biochimie. 87:99–109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dummler B and Hemmings BA: Physiological
roles of PKB/Akt isoforms in development and disease. Biochem Soc
Trans. 35:231–235. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cohen MM Jr: The AKT genes and their roles
in various disorders. Am J Med Genet A 161A. 2931–2937. 2013.
View Article : Google Scholar
|
|
49
|
Hadj Sassi A, Monteil J, Sauvant P and
Atgié C: Overexpression of caveolin-3-enhanced protein synthesis
rather than proteolysis inhibition in C2C12 myoblasts: Relationship
with myostatin activity. J Physiol Biochem. 68:683–690. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yudushkin I: Getting the Akt together:
Guiding intracellular Akt activity by PI3K. Biomolecules.
9:E672019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cho H, Thorvaldsen JL, Chu Q, Feng F and
Birnbaum MJ: Akt1/PKBalpha is required for normal growth but
dispensable for maintenance of glucose homeostasis in mice. J Biol
Chem. 276:38349–38352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Garofalo RS, Orena SJ, Rafidi K, Torchia
AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks
JR, et al: Severe diabetes, age-dependent loss of adipose tissue,
and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin
Invest. 112:197–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
George S, Rochford JJ, Wolfrum C, Gray SL,
Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini
CL, et al: A family with severe insulin resistance and diabetes due
to a mutation in AKT2. Science. 304:1325–1328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Katome T, Obata T, Matsushima R, Masuyama
N, Cantley LC, Gotoh Y, Kishi K, Shiota H and Ebina Y: Use of RNA
interference-mediated gene silencing and adenoviral overexpression
to elucidate the roles of AKT/protein kinase B isoforms in insulin
actions. J Biol Chem. 278:28312–28323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang S and Czech MP: The GLUT4 glucose
transporter. Cell Metab. 5:237–252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fecchi K, Volonte D, Hezel MP, Schmeck K
and Galbiati F: Spatial and temporal regulation of GLUT4
translocation by flotillin-1 and caveolin-3 in skeletal muscle
cells. FASEB J. 20:705–707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pedersen O, Bak JF, Andersen PH, Lund S,
Moller DE, Flier JS and Kahn BB: Evidence against altered
expression of GLUT1 or GLUT4 in skeletal muscle of patients with
obesity or NIDDM. Diabetes. 39:865–870. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ryder JW, Yang J, Galuska D, Rincón J,
Björnholm M, Krook A, Lund S, Pedersen O, Wallberg-Henriksson H,
Zierath JR and Holman GD: Use of a novel impermeable biotinylated
photolabeling reagent to assess insulin- and hypoxia-stimulated
cell surface GLUT4 content in skeletal muscle from type 2 diabetic
patients. Diabetes. 49:647–654. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Konno S, Alexander B, Zade J and Choudhury
M: Possible hypoglycemic action of SX-fraction targeting insulin
signal transduction pathway. Int J Gen Med. 6:181–187. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dewulf M, Köster DV, Sinha B, Viaris de
Lesegno C, Chambon V, Bigot A, Bensalah M, Negroni E, Tardif N,
Podkalicka J, et al: Dystrophy-associated caveolin-3 mutations
reveal that caveolae couple IL6/STAT3 signaling with mechanosensing
in human muscle cells. Nat Commun. 10:19742019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Pál E, Zima J, Hadzsiev K, Ito YA, Hartley
T; Care4Rare Canada Consortium, ; Boycott KM and Melegh B: A novel
pathogenic variant in TNPO3 in a Hungarian family with limb-girdle
muscular dystrophy 1F. Eur J Med Genet. 62:1036622019. View Article : Google Scholar : PubMed/NCBI
|
